Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)
Clinical trial NCT02266706 · COMPLETED
Trial details
- NCT number
- NCT02266706
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-17
- Primary completion
- 2017-06-08
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.